Literature DB >> 24824848

Overexpression of far upstream element (FUSE) binding protein (FBP)-interacting repressor (FIR) supports growth of hepatocellular carcinoma.

Mona Malz1, Michael Bovet, Jana Samarin, Uta Rabenhorst, Carsten Sticht, Michaela Bissinger, Stephanie Roessler, Justo Lorenzo Bermejo, Marcus Renner, Diego Francesco Calvisi, Stephan Singer, Matthias Ganzinger, Achim Weber, Norbert Gretz, Martin Zörnig, Peter Schirmacher, Kai Breuhahn.   

Abstract

UNLABELLED: The far upstream element binding protein (FBP) and the FBP-interacting repressor (FIR) represent molecular tools for transcriptional fine tuning of target genes. Strong overexpression of FBP in human hepatocellular carcinoma (HCC) supports tumor growth and correlates with poor patient prognosis. However, the role of the transcriptional repressor FIR in hepatocarcinogenesis remains poorly delineated. We show that overexpression of FIR correlates with tumor dedifferentiation and tumor cell proliferation in about 60% of primary HCCs. Elevated FIR levels are associated with genomic gains of the FIR gene locus at chromosome 8q24.3 in human HCC specimens. In vitro, nuclear enrichment of FIR supports HCC cell proliferation and migration. Expression profiling of HCC cells after small interfering RNA (siRNA)-mediated silencing of FIR identified the transcription factor DP-1 (TFDP1) as a transcriptional target of FIR. Surprisingly, FIR stimulates the expression of FBP in a TFDP1/E2F1-dependent manner. FIR splice variants lacking or containing exon 2 and/or exon 5 are expressed in the majority of HCCs but not in normal hepatocytes. Specific inhibition of FIR isoforms with and without exon 2 revealed that both groups of FIR splice variants facilitate tumor-supporting effects. This finding was confirmed in xenograft transplantation experiments with lentiviral-infected short hairpin RNA (shRNA) targeting all FIR variants as well as FIR with and without exon 2.
CONCLUSION: High-level nuclear FIR does not facilitate repressor properties but supports tumor growth in HCC cells. Thus, the pharmacological inhibition of FIR might represent a promising therapeutic strategy for HCC patients with elevated FIR expression.
© 2014 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24824848     DOI: 10.1002/hep.27218

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  17 in total

1.  PI3K/AKT/mTOR-dependent stabilization of oncogenic far-upstream element binding proteins in hepatocellular carcinoma cells.

Authors:  Jana Samarin; Vibor Laketa; Mona Malz; Stephanie Roessler; Ilan Stein; Elad Horwitz; Stephan Singer; Eleni Dimou; Antonio Cigliano; Michaela Bissinger; Christine Susanne Falk; Xin Chen; Steven Dooley; Eli Pikarsky; Diego Francesco Calvisi; Carsten Schultz; Peter Schirmacher; Kai Breuhahn
Journal:  Hepatology       Date:  2016-01-14       Impact factor: 17.425

Review 2.  Alternative splicing of DNA damage response genes and gastrointestinal cancers.

Authors:  Bahityar Rahmutulla; Kazuyuki Matsushita; Fumio Nomura
Journal:  World J Gastroenterol       Date:  2014-12-14       Impact factor: 5.742

3.  Long non-coding RNA CARLo-5 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients.

Authors:  Fuqiang Wang; Chengrong Xie; Wenxing Zhao; Zhigang Deng; Huili Yang; Qinliang Fang
Journal:  Clin Exp Med       Date:  2015-10-03       Impact factor: 3.984

4.  Far Upstream Element Binding Protein Plays a Crucial Role in Embryonic Development, Hematopoiesis, and Stabilizing Myc Expression Levels.

Authors:  Weixin Zhou; Yang Jo Chung; Edgardo R Parrilla Castellar; Ying Zheng; Hye-Jung Chung; Russell Bandle; Juhong Liu; Lino Tessarollo; Eric Batchelor; Peter D Aplan; David Levens
Journal:  Am J Pathol       Date:  2016-01-14       Impact factor: 4.307

Review 5.  The master regulator FUBP1: its emerging role in normal cell function and malignant development.

Authors:  Lydie Debaize; Marie-Bérengère Troadec
Journal:  Cell Mol Life Sci       Date:  2018-10-20       Impact factor: 9.261

6.  Haploinsufficiency of the c-myc transcriptional repressor FIR, as a dominant negative-alternative splicing model, promoted p53-dependent T-cell acute lymphoblastic leukemia progression by activating Notch1.

Authors:  Kazuyuki Matsushita; Kouichi Kitamura; Bahityar Rahmutulla; Nobuko Tanaka; Takayuki Ishige; Mamoru Satoh; Tyuji Hoshino; Satoru Miyagi; Takeshi Mori; Sakae Itoga; Hideaki Shimada; Takeshi Tomonaga; Minoru Kito; Yaeko Nakajima-Takagi; Shuji Kubo; Chiaki Nakaseko; Masahiko Hatano; Takashi Miki; Masafumi Matsuo; Masaki Fukuyo; Atsushi Kaneda; Atsushi Iwama; Fumio Nomura
Journal:  Oncotarget       Date:  2015-03-10

7.  A20/TNFAIP3 Discriminates Tumor Necrosis Factor (TNF)-Induced NF-κB from JNK Pathway Activation in Hepatocytes.

Authors:  Federico Pinna; Michaela Bissinger; Katharina Beuke; Nicolas Huber; Thomas Longerich; Ursula Kummer; Peter Schirmacher; Sven Sahle; Kai Breuhahn
Journal:  Front Physiol       Date:  2017-08-23       Impact factor: 4.566

8.  Disturbed alternative splicing of FIR (PUF60) directed cyclin E overexpression in esophageal cancers.

Authors:  Yukiko Ogura; Tyuji Hoshino; Nobuko Tanaka; Guzhanuer Ailiken; Sohei Kobayashi; Kouichi Kitamura; Bahityar Rahmutulla; Masayuki Kano; Kentarou Murakami; Yasunori Akutsu; Fumio Nomura; Sakae Itoga; Hisahiro Matsubara; Kazuyuki Matsushita
Journal:  Oncotarget       Date:  2018-05-01

9.  FIR haplodeficiency promotes splicing to pyruvate kinase M2 in mice thymic lymphoma tissues revealed by six-plex tandem mass tag quantitative proteomic analysis.

Authors:  Asako Kimura; Kouichi Kitamura; Guzhanuer Ailiken; Mamoru Satoh; Toshinari Minamoto; Nobuko Tanaka; Fumio Nomura; Kazuyuki Matsushita
Journal:  Oncotarget       Date:  2017-07-07

10.  Anti-FIRs (PUF60) auto-antibodies are detected in the sera of early-stage colon cancer patients.

Authors:  Sohei Kobayashi; Tyuji Hoshino; Takaki Hiwasa; Mamoru Satoh; Bahityar Rahmutulla; Sachio Tsuchida; Yuji Komukai; Tomoaki Tanaka; Hisahiro Matsubara; Hideaki Shimada; Fumio Nomura; Kazuyuki Matsushita
Journal:  Oncotarget       Date:  2016-12-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.